

Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery

May 29, 2020

Source URL: <https://prod1.novartis.com/us-en/news/media-releases/novartis-announces-long-term-relapse-free-survival-benefit-high-risk-stage-iii-melanoma-patients-treated-tafinlar-mekinist-following-surgery-0>

List of links present in page

1. <https://prod1.novartis.com/us-en/us-en/news/media-releases/novartis-announces-long-term-relapse-free-survival-benefit-high-risk-stage-iii-melanoma-patients-treated-tafinlar-mekinist-following-surgery-0>